Virtual Library

Start Your Search

Elisa Caiola



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      188TiP - Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial (ID 497)

      12:30 - 13:00  |  Author(s): Elisa Caiola

      • Abstract
      • Slides

      Background

      LKB1 inactive (LKB1i) lung adenocarcinoma (LA) has an aggressive behavior and is resistant to immunotherapy (IO). LKB1i cells are vulnerable to nutrient starvation. Based on preclinical data showing a synergy cisplatin-metformin, we hypothesized that combining platinum-based chemotherapy (CT) with metformin +/- a calorie-restricted, low-carbohydrate, low-protein diet known as Fasting Mimicking Diet (FMD) may improve the efficacy of CT in patients (pts) with LKB1i LA.

      a9ded1e5ce5d75814730bb4caaf49419 Trial design

      FAME is a monocentric, open label, double arm, non comparative, randomized, single stage, pick-the-winner phase II trial. Primary objective is Progression Free Survival (PFS), evaluated in comparison with a historical cohort of pts treated with CT. Secondary objectives consist in studying experimental treatment toxicity, response rate, overall survival, metabolic changes in blood, urine and stool, correlation between LKB1 mutation status and LKB1 protein expression. Main inclusion criteria are: advanced LKB1i LA, absence of EGFR mutations and ALK/ROS1 rearrangements, PDL1 expression < 50%, performance status 0-1. Main exclusion criteria are: body mass index <20 kg/m2, weight loss ≥5% in the previous 3 months, diabetes mellitus, active brain metastases, baseline fasting glucose ≤65 mg/dL, arterial pO2 <70 mmHg, high blood lactates. Eligible pts will be randomized 1:1 to up to 4 cycles of platinum-pemetrexed CT + metformin, or up to 4 cycles of platinum-pemetrexed CT + metformin + FMD. After 4 cycles, stable/responding pts will continue pemetrexed + metformin until progression or toxicity. Forty-one pts per arm will be necessary to identify a 4.4 mos increase in median PFS. Brookmeyer-Crowley test will be used with an α tail of .15 and a power of .8 mos. Assuming a dropout rate of 5%, the number of pts to enroll will be 88.

      d9b324a48b043b3d87bc9b3fe620f260 Clinical trial identification

      NCT03709147, first posted on 17 October 2018; EudraCT: 2018-000788-95.

      7a6a3ffa2dadc03a6151ee2c4d6fa383 Legal entity responsible for the study

      Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

      213f68309caaa4ccc14d5f99789640ad Funding

      AIRC (Associazione Italiana per la Ricerca sul Cancro) Investigator Grant 2017.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.